The largest community of pharma leaders

BIOQUAL Presents Financial Results for Fiscal Year 2020 and Declares Dividend

ROCKVILLE, Md.–()–BIOQUAL ((OTC Pink: BIOQ) (www.bioqual.com):

 

2020

 

 

2019

 

 

Revenue

$

46,360,201

 

$

39,478,079

 

 

Income Before Income Tax

$

5,488,938

 

$

3,709,246

 

 

Net Income

$

4,230,938

 

$

2,830,875

 

 

Basic Earnings per Share

 

 

 

 

of Common Stock

$

4.74

 

$

3.17

 

Diluted Earnings per Share

 

 

 

 

of Common Stock

$

4.73

 

$

3.17

 

Weighted Average

 

 

 

 

Number of Shares Outstanding

 

 

 

For Basic Per Share

 

893,416

 

 

893,416

 

Weighted Average

 

 

 

 

Number of Shares Outstanding

 

 

 

For Diluted Earnings Per Share

 

893,971

 

 

893,655

BIOQUAL’s Board of Directors has declared a dividend of $1.10 per share for shareholders of record on September 28, 2020, payable on October 21, 2020. This is the nineteenth dividend declared by BIOQUAL.

Statements herein that are not descriptions of historical facts are forward-looking and subject to risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors including risks relating to the ability to continue to extend current government contracts; the Company’s ability to obtain new government or commercial contracts; continued demand for the use of animal models in scientific research; the Company’s ability to perform under its contracts in accordance with the requirements of the contracts; the actual costs incurred in performing the Company’s contracts and its ability to manage its costs, including its capital expenditures; dependence on third parties; future capital needs; the ability to fund its capital needs through the use of its cash on hand and line of credit; and the future availability and cost of financing/capital sources to the Company.

Source

Recent Articles

AVROBIO to Present at Two Upcoming Investor Conferences

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene...

Global Neurofibromatosis Treatment Drugs Market to Surpass US$ 21,223.7 Million by 2027, Says Coherent Market Insights (CMI)

SEATTLE--(BUSINESS WIRE)-- #NeurofibromatosisTreatment--The Asia Pacific is expected to witness significant growth...

FDA Approves Nucala as the First and Only Biologic Treatment for Hypereosinophilic Syndrome (HES)

LONDON--(BUSINESS WIRE)--GlaxoSmithKline plc (GSK) (LSE/NYSE: GSK) today announced the US Food...

Novocure Honors Mesothelioma Day with Activities to Raise Awareness of Mesothelioma and Support the Community

ST. HELIER, Jersey--(BUSINESS WIRE)--Novocure announced today initiatives to bring attention to...

Veracyte Receives ADLT Status for Envisia Genomic Classifier From Centers for Medicare and Medicaid Services

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte Receives ADLT Status for Envisia Genomic...
2020 Call for Writers

Are you looking to inspire others in the pharma industry through your writing? You’re invited to submit your articles to become a Featured Writer for The Pharmaceutical Marketing Group website.